Story · Medicine & Biotech

Additional value of germline genomic scores beyond prostate-specific antigen alone for long-term and near-term prostate cancer risk

1 outlet · first reported by medRxiv (all subjects) on

We evaluated whether germline genomic risk complements prostate-specific antigen (PSA) for prostate cancer early detection. P-CARE integrates a 601-variant polygenic hazard score, family history, and genetic ancestry. Long-term outcomes and clinically significant prostate cancer (csPCa) detection… (medRxiv (all subjects))

Coverage, in order

  1. medRxiv (all subjects) obscure study
    Additional value of germline genomic scores beyond prostate-specific antigen alone for long-term and near-term prostate cancer risk

    We evaluated whether germline genomic risk complements prostate-specific antigen (PSA) for prostate cancer early detection. P-CARE integrates a 601-variant polygenic hazard score, family history, and genetic ancestry. Long-term outcomes and clinically significant prostate cancer (csPCa) detection…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.